Industry

We are working in partnership with the pharmaceutical industry to bring new and improved treatments to patients.

Information for industry

The BEACON trial is an important and very timely opportunity to obtain comparative data on the key systemic therapies used to treat moderate to severe adult eczema. It will provide the first ever comprehensive evidence on the comparative effectiveness, tolerability and cost-effectiveness of oral ciclosporin, subcutaneous methotrexate, subcutaneous dupilumab and oral abrocitinib.

BEACON has been set up to facilitate continuation as a multi-arm multi-stage platform trial to permit the inclusion of additional treatment arms in the future. To our knowledge, this represents the first platform trial for inflammatory skin disease. The first additional arm in BEACON was abrocitinib, added in February 2025 , funded by Pfizer. An aligned bioresource for biomarker discovery will run in parallel to inform future personalised therapy.

We would be delighted to speak to industry partners regarding any aspect of our programme and the potential inclusion of novel therapeutics into the platform.

If you are interested in discussing this, please contact catherine.smith@kcl.ac.uk, copying in BEACON@kcl.ac.uk.

For more information about eczema, please contact the National Eczema Society: https://eczema.org/